Parabilis Medicines, Inc. (NASDAQ: PBLS) is a Healthcare company (Biotechnology) with a market capitalization of $3.4B. The Maz Rating grades it against the other companies in its sector.
Parabilis Medicines, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $28.25, Parabilis Medicines, Inc. trades at 1509.0x sales and 3.4x book value. Over the last twelve months it generated about $2M of revenue and a net loss of $229M. It runs a gross margin of -20.8%, an operating margin of -8381.7% and a net margin of -7828.5%. It shows return on equity of -23.1%, return on invested capital of -17.7% and a free cash flow yield of -3.7%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 12.88. Over the past 52 weeks the share price ranged from $20.00 to $42.49, with a beta of 5.03.
Parabilis Medicines, Inc. does not currently pay a dividend.
Parabilis Medicines, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Parabilis Medicines, Inc. (PBLS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.05% / 30% · (Cash+Inv) / Mkt Cap (36m) 26.6% / 30% · Interest income / Revenue 490.5% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.05% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 21.6% / 33% · Receivables / Mkt Cap (36m) 0.01% / 49% · Interest income / Revenue 490.5% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.05% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 21.6% / 33.33% · Receivables / Mkt Cap (24m) 0.01% / 33.33% · Interest income / Revenue 490.5% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.64% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 86.3% / 33.33% · Receivables / Avg Assets (4Q) 0.02% / 33.33% · Interest income / Revenue 490.5% / 5% | Fail |
| FTSE | Debt / Total Assets 0.18% / 33.33% · (Cash+ST Inv) / Total Assets 77.1% / 33.33% · (Cash+Recv) / Total Assets 77.1% / 33.33% · Interest income / Revenue 490.5% / 5% | Fail |
No. As of September 2026, Parabilis Medicines, Inc. (PBLS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Parabilis Medicines, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 490.5% of each dividend: Parabilis Medicines, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.